Cancer Diagnostics Market Surpasses US$171.90 Billion in 2023; Projected Growth at 7.23% CAGR from 2024 to 2030

The worldwide cancer diagnostics market is predicted to be priced at around US$ 280.37 billion by 2030, according to Renub Research. Cancer diagnostics is the process of coming across biomarkers, proteins, and other signs and symptoms that result in the detection of a cancerous tumor. Diagnostic checking is used to verify or rule out the presence of illness, the progression of the disease, the timetable, and the treatment consequences. Imaging, tumor biopsy, laboratory assessments, endoscopic tests, surgical techniques, and genetic testing are all feasible cancer diagnostic strategies.
The global cancer diagnostics market reached US$171.90 Billion in 2023 and is forecast to expand at a CAGR of 7.23% from 2024 to 2030. The technique of detecting several proteins, biomarkers, and sure signs that result in the discovery of the presence of a malignant tumor in a patient is referred to as cancer diagnostics.

Read More: https://www.renub.com/cancer-diagnostics-market-p.php

The diagnosis approach is aided by the detection of unique proteins and biomarkers, which is probably not unusual in cancer ailments. The approach to figuring out cancer includes the use of specific technologies and devices designed for cancer diagnostics. A global upward push in the superiority of cancers is one of the most important factors facilitating market growth. For instance, as consistent with the Pan American Health Organization (PAHO), an anticipated 20 million new instances and 10 million deaths are anticipated in 2023, and the once-a-year-wide variety of stated cases is expected to reach approximately 30 million by the year 2040. The need for the improvement of diagnostic alternatives that can discover the disease at an early level, enhance disease control, and decrease mortality may propel market growth. It is likewise indicated that one in six women and one in five men are likely to develop most cancers at some unspecified time in the future of their lives.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=cancer-diagnostics-market-p.php

Key Player in the Cancer Diagnostics Market
In the global cancer diagnostics sector, notable members encompass Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Pfizer, Inc., Koninklijke Philips N.V., and BioMérieux.

 In June 2023, Paige AI, Inc. brought its AI-powered "Paige Breast Suite," aiding pathologists in breast cancer diagnosis.
 HALO Breast Care Center launched HALO PathWay in February 2023, offering comprehensive breast cancer screening, which includes genetic testing and superior imaging.
 Responding to USPSTF tips in September 2023, Hologic emphasised mammography's function in early detection.
 Myriad Genetics and SimonMed partnered in April 2023 to provide customized cancer threat tests.
 F. Hoffmann-La Roche elevated collaboration with Janssen in February 2023 for accomplice diagnostics.
 Quest Diagnostics received Haystack Oncology in April 2023, aiming to enhance its MRD testing offerings.
 Blue Earth Diagnostics obtained FDA approval for POSLUMA in June 2023, an excessive-affinity PSMA-centered PET imaging agent for prostate cancer detection.

Breast cancer diagnostics seize a tremendous part of the worldwide market.

Breast cancer diagnostics command a sizeable share of the global marketplace, underscoring the call for powerful gear in combating the ailment. This reflects widespread investments in enhancing diagnostic abilities for early detection and remedy. According to the American Cancer Society, around 281,550 new cases and 49,290 related deaths are predicted within the U.S. alone in 2021. Globally, breast cancer, recognized by the WHO as the most regularly occurring cancer, will have over 2 million new cases in 2021. These figures emphasize the crucial necessity for advanced diagnostic solutions to resource early detection, unique diagnosis, and effective remedy techniques.

One of the vast segments within the worldwide cancer diagnostics market relates to imaging check types.
In the quest for early detection and tailor-made remedies, healthcare systems place a premium on imaging check alternatives, which play a vital role in cancer diagnostics. These checks are quintessential equipment, permitting clinicians to visualize tumors, assess their characteristics, and formulate particular remedy plans tailored to men or women's' wishes. In March 2022, college students at the University of Notre Dame created NearWave Imager, an innovative tool for detecting and monitoring breast cancer. This development reflects ongoing efforts to develop most cancer diagnostic imaging, probably riding a section boom.
Diagnostic facilities play a dominant role in the global cancer diagnostics market.

Diagnostic centers are pivotal in propelling the global cancer diagnostics market by engaging in numerous assessments like imaging scans, biopsies, and blood checks, facilitating early cancer detection. With a focus on preventive healthcare, those centers are poised for a sustained boom. NHL ranks among the most common cancers within the U.S., with over eighty,000 cases expected in 2022, emphasizing the growing demand for cancer diagnostics, mainly among the various elderly populations.

The United States has the capability to maintain its dominance within the global market.

The United States leads the global cancer diagnostics market with advanced infrastructure, R&D, and a focal point on early detection. Collaborations among healthcare entities and tech firms bolster this position. Rising breast and colon cancer instances in the US drive a market increase. Government initiatives just like the Cancer Moonshot similarly propel the marketplace. ACS tasks new most cancer cases to boom from 1,918,030 in 2022 to at least one,958,310 via 2023, with breast most cancer instances growing from 290,560 to 300,590 and colon most cancer instances from 80,690 to 81,860.

Application - Global Cancer Diagnostics Market breakup in 12 viewpoints:

1. Breast Cancer
2. Colorectal Cancer
3. Cervical Cancer
4. Lung Cancer
5. Prostate Cancer
6. Skin Cancer
7. Blood Cancer
8. Kidney Cancer
9. Liver Cancer
10. Pancreatic Cancer
11. Ovarian Cancer
12. Others

Test Type - Global Cancer Diagnostics Market breakup in 6 viewpoints:

1. Tumor Biomarkers Tests
2. Imaging
3. Biopsy
4. Liquid Biopsy
5. Immunohistochemistry
6. In Situ Hybridization

End-User - Global Cancer Diagnostics Market breakup in 4 viewpoints:

1. Diagnostic Centers
2. Hospitals and Clinics
3. Research Institutes
4. Others

Country - Global Cancer Diagnostics Market of 25 Countries:

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. llumina
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc.
4. QIAGEN N.V.
5. Roche Holding AG.
6. Pfizer, Inc.
7. Koninklijke Philips N.V.
8. bioMérieux

Browse Related Report:

Cervical Cancer Screening Market: https://www.renub.com/global-cervical-cancer-screening-market-and-patients-by-test-type-pap-smear-hpv-dna-via-forecast-1009-p.php

Lung Cancer Diagnostics Market: https://www.renub.com/lung-cancer-diagnostics-market-p.php

Prostate Cancer Diagnostics Market: https://www.renub.com/prostate-cancer-diagnostics-market-p.php

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Contact Us:

Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: info@renub.com
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com

This release was published on openPR.